Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Travera Inc
7 Hills Pharma, LLC
Seagen Inc.
Genmab
KaliVir Immunotherapeutics
Roswell Park Cancer Institute
Sotio Biotech Inc.
Massachusetts General Hospital
Nuvectis Pharma, Inc.
Dutch Society of Physicians for Pulmonology and Tuberculosis
A2 Biotherapeutics Inc.
A2 Biotherapeutics Inc.
Takeda
Seagen Inc.
Novartis
Stanford University
VM Oncology, LLC
Bristol-Myers Squibb
HiFiBiO Therapeutics
Stella Pharma Corporation
Actym Therapeutics, Inc.
Sanofi
Nurix Therapeutics, Inc.
TCR2 Therapeutics
TCR2 Therapeutics
Incyte Corporation
NuCana plc
A2 Biotherapeutics Inc.
Telix Pharmaceuticals (Innovations) Pty Limited
Ascentage Pharma Group Inc.
University College, London
Alliance for Clinical Trials in Oncology
Checkpoint Therapeutics, Inc.
BerGenBio ASA
Aminex Therapeutics, Inc.
Radboud University Medical Center
Travera Inc
Aromics Therapeutics
Molecular Templates, Inc.
NanoAlvand
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Swiss Cancer Institute
University of Leeds
NGM Biopharmaceuticals, Inc
Centre Hospitalier Universitaire Vaudois
Massachusetts General Hospital
Massachusetts General Hospital
Western Sydney Local Health District